BACKGROUND: Microcystic adnexal carcinoma (MAC) is a very rare cancer of the skin. It has only been described previously in case reports and small retrospective series. OBJECTIVE: To analyze and summarize data from the National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) database regarding MAC. METHODS: The SEER 1973 to 2004 database was investigated, and patients with MAC were identified. A statistical analysis was performed. RESULTS: Two hundred twenty-three patients were identified. Predominant site of disease was the head and neck skin (74%). There was only 1 case of recorded metastatic disease. Lymph nodes were pathologically involved in 1%. The 10-year overall survival was 86.4% (Standard Error [SE]: 3.3%). US census population-matched relative survival was 97.7% at 10 years (SE: 5.2%). LIMITATIONS: This study is limited by the retrospective nature of the SEER database. CONCLUSIONS: MAC is locally invasive, and rarely metastasizes to lymph nodes. Overall and population-matched relative survival is excellent.
BACKGROUND:Microcystic adnexal carcinoma (MAC) is a very rare cancer of the skin. It has only been described previously in case reports and small retrospective series. OBJECTIVE: To analyze and summarize data from the National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) database regarding MAC. METHODS: The SEER 1973 to 2004 database was investigated, and patients with MAC were identified. A statistical analysis was performed. RESULTS: Two hundred twenty-three patients were identified. Predominant site of disease was the head and neck skin (74%). There was only 1 case of recorded metastatic disease. Lymph nodes were pathologically involved in 1%. The 10-year overall survival was 86.4% (Standard Error [SE]: 3.3%). US census population-matched relative survival was 97.7% at 10 years (SE: 5.2%). LIMITATIONS: This study is limited by the retrospective nature of the SEER database. CONCLUSIONS: MAC is locally invasive, and rarely metastasizes to lymph nodes. Overall and population-matched relative survival is excellent.
Authors: Hanneke Stam; Bart A van de Wiel; W Martin C Klop; Biljana Zupan-Kajcovski; Soe Janssens; M Baris Karakullukcu; Vincent van der Noort; Peter J F M Lohuis Journal: Eur Arch Otorhinolaryngol Date: 2014-10-16 Impact factor: 2.503
Authors: Stanislav N Tolkachjov; Adam R Schmitt; John G Muzic; Amy L Weaver; Christian L Baum Journal: Dermatol Surg Date: 2017-01 Impact factor: 3.398
Authors: Reshma Jagsi; Justin E Bekelman; Aileen Chen; Ronald C Chen; Karen Hoffman; Ya-Chen Tina Shih; Benjamin D Smith; James B Yu Journal: Int J Radiat Oncol Biol Phys Date: 2014-09-01 Impact factor: 7.038
Authors: May P Chan; Komal R Plouffe; Chia-Jen Liu; Nallasivam Palanisamy; Shannon Carskadon; Lili Zhao; Rosalynn M Nazarian; Alison B Durham; Timothy M Johnson; Aleodor A Andea; Rajiv M Patel; Lori Lowe; Douglas R Fullen; Noah A Brown; Scott A Tomlins; Aaron M Udager; Paul W Harms Journal: Mod Pathol Date: 2019-12-19 Impact factor: 7.842